Compare ONL & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONL | RCEL |
|---|---|---|
| Founded | 2021 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.5M | 114.3M |
| IPO Year | N/A | N/A |
| Metric | ONL | RCEL |
|---|---|---|
| Price | $2.02 | $3.41 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 5 |
| Target Price | N/A | ★ $11.75 |
| AVG Volume (30 Days) | ★ 311.3K | 196.2K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | ★ 3.90% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $149,775,000.00 | $72,401,000.00 |
| Revenue This Year | N/A | $13.12 |
| Revenue Next Year | N/A | $27.56 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 20.59 |
| 52 Week Low | $1.46 | $3.33 |
| 52 Week High | $4.25 | $14.16 |
| Indicator | ONL | RCEL |
|---|---|---|
| Relative Strength Index (RSI) | 35.31 | 36.15 |
| Support Level | $1.97 | $3.33 |
| Resistance Level | $2.13 | $3.58 |
| Average True Range (ATR) | 0.10 | 0.18 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 28.21 | 14.88 |
Orion Properties Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased on a single-tenant net lease basis to creditworthy clients. The portfolio of the company includes traditional office buildings, governmental offices, medical offices, laboratories, and others. The Company operates in one business segment: direct ownership and operation of commercial real estate.
Avita is a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently in rollout across the approximately 136 US burn centers. Despite having product approval in Australia, Europe, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region. However, it is expected to launch in Japan via distribution partner Cosmotec in second-half fiscal 2022. Avita is domiciled, and has its primary listing, in the US.